You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
國家醫保局就藥品續約及競價規則分類徵意見
國家醫保局研究起草《談判藥品續約規則(2023年版徵求意見稿)》及《非獨家藥品競價規則(徵求意見稿)》向社會公開徵求意見。 其中,非獨家藥品競價規則提出,藥品通過競價納入醫保目錄的,取各企業報價中的最低者作為該通用名藥品的支付標準。如企業報價低於醫保支付意願的70%,以醫保支付意願的70%作為該藥品的支付標準。 談判藥品續約規則提出,獨家藥品、協議期基金實際支出未超過基金支出預算的200%,且未來兩年的基金支出預算增幅合理的藥品可以簡易續約,續約有效期為兩年。一類化學藥品、一類治療用生物製品、一類和三類中藥,續約時如基金實際支出/基金支出預算值大於110%,企業可申請通過重新談判確定降幅。如談判失敗,將調出目錄。 談判藥品續約規則提出,非獨家藥品中,凡於2019年目錄內談判藥品,連續兩個協議周期均未調整支付標準和支付範圍的獨家藥品;談判進入目錄且連續納入目錄「協議期內談判藥品部分」超過八年的藥品,可納入常規目錄管理。 而非獨家藥品競價規則條件為,經專家評審,建議新增納入醫保藥品目錄的非獨家藥品,國家組織藥品集中帶量採購中選藥品和政府定價藥品除外。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account